Day: February 5, 2025

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, today announced the Company has received Clinical Trial Authorization from Health Canada to initiate its clinical trial for its lead asset, Decoy20. This approval will allow the Company to expand its ongoing U.S. clinical trial, INDP-D101, to Canadian sites, broadening patient recruitment and enhancing its clinical research program. The trial will enroll patients in Canada under the current protocol, which involves weekly dosing of Decoy20. Indaptus also plans to submit an amendment to Health Canada to incorporate its upcoming combination trial, which pairs Decoy20 with Beigene’s PD-1 checkpoint inhibitor, tislelizumab. Jeffrey...

Rapid menu expansion with new high-plex human and mouse neurobiology panels joining the recently launched Human IO60 and Mouse FFPE IO Panels The new offerings solidify leadership in spatial biology and broaden reach to new verticals MARLBOROUGH, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) — Akoya Biosciences, a spatial proteomics leader, announced its reagent product roadmap today, featuring new ultrahigh-plex neurobiology panels for human and mouse applications. Building on the success of the Human IO60 and Mouse FFPE IO panels, which debuted at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in November 2024, this roadmap represents the next step in the company’s mission to provide cutting-edge tools for advancing research across multiple market including oncology, inflammatory disease and neurobiology. Transforming...

Tel Aviv, Israel, Feb. 05, 2025 (GLOBE NEWSWIRE) — ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “Company or “ParaZero”), an aerospace company focused on safety systems for commercial unmanned aircrafts and defense Counter UAS systems, announced today the successful demonstration of its DropAir Precision airdrop system in collaboration with a leading global defense company. The demonstration showcased the DropAir system’s ability to safely and precisely deliver critical supplies under challenging operational conditions. During the test, ParaZero’s proprietary DropAir technology was deployed in multiple high-altitude drone airdrops. The system’s advanced parachute mechanism activated at low altitude, ensuring minimal drift and precise landings, even in complex environments. Following the successful demonstration, ParaZero...

American Rebel Holdings IncAmerican Rebel LightAppearance Scheduled to Air on Friday, February 7 Broadcast Between 10 – 11 am Eastern Nashville, TN, Feb. 05, 2025 (GLOBE NEWSWIRE) — American Rebel Holdings, Inc. (NASDAQ: AREB) (“American Rebel” or the “Company”), creator of American Rebel Beer (americanrebelbeer.com) and a designer, manufacturer, and marketer of branded safes, personal security and self-defense products and apparel (americanrebel.com), is excited to announce that its CEO Andy Ross will appear on the Friday, February 7 broadcast of Morning Blend (abcactionnews.com/morning-blend) on ABC Action News Tampa. Andy’s segment will appear between 10- 11 am Eastern Standard Time. Andy will promote the SCAG Power Equipment PRO Superstar Shootout (prosuperstarshootout.com) and his Saturday...

MONTREAL, Feb. 05, 2025 (GLOBE NEWSWIRE) — HPQ Silicon Inc. (“HPQ” or the “Company”) (TSX-V: HPQ, OTCQB: HPQFF, FRA: O08), a technology company specializing in green engineering of silica- and silicon-based materials is pleased to update shareholders on the latest exceptional battery results from its France-based partner, NOVACIUM SAS (Novacium). The following summarizes our test results at 900 cycles on 18650 batteries:GEN3 silicon-anode material batteries demonstrate exceptional capacity and durability [1], They Outperform leading commercial 18650 battery cells [2,3,4,5,6), They achieve exceptionally high average Coulombic Efficiency of 99.88% [7], They deliver an outstanding 31% cumulative energy gain [8], over graphite benchmark batteries.Test Results at 900 Cycles Validate Unique Capabilities of GEN3 Silicon Anode performance At...

Bagsværd, Denmark, 5 February 2025 – Novo Nordisk A/S has filed its Annual Report 2024 on Form 20-F for the financial year 2024 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2024. The reports are available at the SEC’s website, www.sec.gov, as well as on novonordisk.com. Shareholders may receive a hard copy of Novo Nordisk’s completed audited financial statements free of charge upon request to investor-relations@novonordisk.com. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure...

Webcast and Conference Call To be Held Wednesday, February 12, 2025, 8:30 am ET NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will issue financial results for its first fiscal quarter on Wednesday, February 12, 2025. Management will host a conference call on Wednesday, February 12, at 8:30 am ET to review financial results and provide an update on the execution of the Company’s growth strategy. Following management’s remarks, there will be a question-and-answer...

HONG KONG, Feb. 05, 2025 (GLOBE NEWSWIRE) — Plutus Financial Group Limited (“the “Company”) (NasdaqCM: PLUT), a Hong Kong-based financial services company, today announced the pricing of its initial public offering (the “Offering”) of 2,100,000 ordinary shares at a public offering price of $4 per ordinary share, for total gross proceeds of $8.4 million, before deducting underwriting discounts and offering expenses. The Offering is being conducted on a firm commitment basis. The ordinary shares are expected to commence trading on Nasdaq Capital Market under the ticker symbol “PLUT” on February 5, 2025. The Company has granted the underwriter an option, exercisable within 45 days from the date of the underwriting agreement, to purchase up to an additional 315,000 ordinary shares at the public offering price,...

Hong Kong, Feb. 05, 2025 (GLOBE NEWSWIRE) — Plutus Financial Group Limited (“the “Company”) (NasdaqCM: PLUT), a Hong Kong-based financial services company, today announced the pricing of its initial public offering (the “Offering”) of 2,100,000 ordinary shares at a public offering price of $4 per ordinary share, for total gross proceeds of $8.4 million, before deducting underwriting discounts and offering expenses. The Offering is being conducted on a firm commitment basis. The ordinary shares are expected to commence trading on Nasdaq Capital Market under the ticker symbol “PLUT” on February 5, 2025. The Company has granted the underwriter an option, exercisable within 45 days from the date of the underwriting agreement, to purchase up to an additional 315,000 ordinary shares at the public offering price,...